BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

In a recent adoptive cell therapy (ACT) clinical trial using autologous tumor-infiltrating lymphocytes (TILs) in patients with metastatic melanoma, we found an association between CD8(+) T cells expressing the inhibitory receptor B- and T-lymphocyte attenuator (BTLA) and clinical response. Here, we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Haymaker, Cara L, Wu, Richard C, Ritthipichai, Krit, Bernatchez, Chantale, Forget, Marie-Andrée, Chen, Jie Qing, Liu, Hui, Wang, Ena, Marincola, Francesco, Hwu, Patrick, Radvanyi, Laszlo G
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4570103/
https://ncbi.nlm.nih.gov/pubmed/26405566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1014246
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados